# A Study of Imlunestrant (LY3484356) in Healthy Women

> **NCT05509816** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 20 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Midazolam
- **DRUG:** Imlunestrant

## Key facts

- **NCT ID:** NCT05509816
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-09-12
- **Primary completion:** 2022-11-30
- **Final completion:** 2022-11-30
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2025-11-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05509816

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05509816, "A Study of Imlunestrant (LY3484356) in Healthy Women". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05509816. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*